Avaliação do Ranelato de Estrôncio na indução ou proteção de osteonecrose. Estudo em ratas ovariectomizadas

Abstract

The aim of this study was to evaluate whether the drug strontium ranelate causes osteonecrosis on the bone tissue of ovariectomized rats, treated or not with bisphosphonates. To perform the research 40 rats were ovariectomized and divided into 4 groups: C (receiving saline solution), BF (1 weekly application of zoledronic acid IP 0.4 mg / kg), RE (625 mg / kg / day strontium ranelate via gavage) and BF+RE (association of bisphosphonate and strontium ranelate at the concentrations indicated above). Exodontia of the lower first molars was performed. After the end of the experimental time, the animals were sacrificed, followed by the following radiographic, microtomographic and histological analyzes. The results indicate that the RE group macroscopically obtained a gradual cicatrization as well as the group C. The BF group presented areas of bone fenestration and dehiscence. When compared radiographically by pixel density, the experimental groups obtained statistical difference with C but not with each other. Regarding the histological analysis, the results pointed out that strontium ranelate does not cause osteonecrosis, this has a tendency to increases the number of osteocytes, blood vessels and reduces the amount of osteoclasts. However, bisphosphonate causes osteonecrosis, reduces the number of blood vessels and osteocytes, but increased the number of osteoclasts. The BF+RE group, despite the reduction of necrosis pictures, was not effective prophylactically for osteonecrosis. Thus, it can be concluded that Ranelate does not cause osteonecrosis, nor can it be used as a prophylactic agent for the disease.